Nashville, Tenn.-based HCA Healthcare said it is targeting adjusted EBITDA growth of between 4% and 6% over the next five years, with such figures expected to start in 2024.
Speaking ahead of an investor day, the for-profit system said Nov. 9 it is also expecting diluted earnings per share growth of between 8% and 12% in the same period.
"While our planning process for 2024 is not complete, we currently believe that our 2024 expectations will fall within the targeted ranges above," CEO Sam Hazen said in a statement.
The predictions also take into account disputed claims with a commercial payer, HCA said. Fuller 2024 guidance is expected at the release of the system's next financial results in January.
HCA reported third-quarter operating income of $1.63 billion on revenue of $16.21 billion. Adjusted EBITDA for the quarter was slightly down on the same period in 2022, totaling $2.88 billion.